Glycemic management after antenatal corticosteroid therapy

Area of Science:

• Obstetrics and Gynecology
• Endocrinology
• Pharmacology

Background:

• Antenatal corticosteroids (ACS) are crucial for fetal lung maturation in preterm deliveries before 34 weeks.
• A known side effect of ACS is the induction of hyperglycemia.
• Managing glucose levels is critical in pregnant women receiving ACS.

Purpose of the Study:

• To review the evidence on the effects of antenatal corticosteroids on glycemic status.
• To outline management strategies for hyperglycemia in pregnant women after ACS use.
• To address implications for women with pre-existing diabetes, gestational diabetes, and normoglycemic women.

Main Methods:

• A comprehensive PubMed search was conducted using keywords: 'steroid,' 'dexamethasone,' 'betamethasone,' 'diabetes,' and 'glucose.'
• Relevant articles were identified and extracted.
• Cross-reference articles were also reviewed to ensure thoroughness.

Main Results:

• Antenatal corticosteroids are associated with significant alterations in glycemic control.
• Hyperglycemia is a common complication, requiring careful monitoring and management.
• Evidence suggests varied impacts based on pre-existing glycemic conditions.

Conclusions:

• Effective management strategies are essential for pregnant women receiving ACS, particularly those with diabetes.
• Further research may be needed to optimize ACS protocols and mitigate glycemic side effects.
• Close collaboration between obstetric and endocrine care is recommended.